Legend Biotech Corp (LEGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Legend Biotech Corp (LEGN) has a cash flow conversion efficiency ratio of -0.017x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.90 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Legend Biotech Corp (LEGN) market capitalisation for the company's overall valuation and market capitalisation.
Legend Biotech Corp - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Legend Biotech Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Legend Biotech Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Legend Biotech Corp ranked by their cash flow conversion efficiency. Explore how high is Legend Biotech Corp's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unilever Indonesia Tbk
JK:UNVR
|
0.413x |
|
Hiwin Technologies Corp
TW:2049
|
0.050x |
|
Life360, Inc. Common Stock
NASDAQ:LIF
|
0.032x |
|
Marketech International Corp
TW:6196
|
0.095x |
|
Asbury Automotive Group Inc
NYSE:ABG
|
0.057x |
|
Brady Corporation
NYSE:BRC
|
0.058x |
|
PTT OIL+RET.BUS.-NVDR- 10
F:7F80
|
-0.360x |
|
Liechtensteinische Landesbank Aktiengesellschaft
F:LLS1
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Legend Biotech Corp (2017–2025)
The table below shows the annual cash flow conversion efficiency of Legend Biotech Corp from 2017 to 2025. View current stock price of Legend Biotech Corp for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.00 Billion | $-100.47 Million | -0.100x | +27.57% |
| 2024-12-31 | $1.04 Billion | $-144.03 Million | -0.138x | +55.96% |
| 2023-12-31 | $1.25 Billion | $-393.28 Million | -0.314x | -16.22% |
| 2022-12-31 | $744.31 Million | $-201.28 Million | -0.270x | -4.37% |
| 2021-12-31 | $765.94 Million | $-198.47 Million | -0.259x | +30.31% |
| 2020-12-31 | $599.82 Million | $-223.00 Million | -0.372x | -154.99% |
| 2019-12-31 | $-122.87 Million | $-83.06 Million | 0.676x | -98.10% |
| 2018-12-31 | $8.65 Million | $307.68 Million | 35.574x | +18315.35% |
| 2017-12-31 | $12.17 Million | $-2.38 Million | -0.195x | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more